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ABSTRACT
Objectives: The physicochemical characteristics of bran of cassava starch flour and bran of cassava flour 
(viz. organoleptic characteristics, pH value, moisture content, total ashes, lipid, protein, starch and fiber 
contents) and biopharmacotechnical parameters (viz. granulometry, flow capacity, angle at rest, outflow 
time and apparent density) were evaluated aiming at assessing their potential use as tablet excipients.
Methodos: Three tablet formulations of venlafaxine hydrochloride were proposed, having as excipients 
bran of cassava flour, bran of cassava starch flour and Starch 1500®. The tablets were produced using two 
different pressures (98±5 MPa and 32±6 Mpa) and their mechanical (hardness and friability) and dissol-
ubility characteristics were evaluated.
Results and Conclusions: The tablets produced with both cassava flours, using higher pressures, pre-
sented similar physicochemical characteristics to those obtained with the excipient Starch1500®, thus 
indicating that cassava flours possess the potential to be used as disintegrating agents in tablets.
Keywords: excipient; tablets; Manihot esculenta
RESUMEN
Objetivos: Se evaluaron características físico-químicas del salvado de harina y del salvado de la fécula 
de mandioca (características organolépticas, pH, humedad, cenizas totales y contenido de lípidos, pro-
teínas, almidones y fibras) y biofarmacotécnicas (granulometría, capacidad de flujo, ángulo en reposo, 
tiempo de salida y densidad aparente) con el objetivo de evaluar el uso de estos residuos como excipien-
tes para comprimidos.
Métodos: Se propusieron tres formulaciones en comprimidos de venlafaxina teniendo como excipientes 
salvado de harina de mandioca, salvado de fécula de mandioca y Starch 1500 ®. Las pastillas se produje-
ron utilizando dos presiones diferentes (98 ± 5 MPa y 32 ± 6 Mpa). Las características mecánicas (dureza 
y friabilidad) y de disolución de los comprimidos se evaluaron.
Resultados y Conclusiones: Los comprimidos producidos con ambos salvados de mandioca, utilizando 
las presiones más elevadas, presentaron características físico-químicas similares a las obtenidas con el 
excipiente Starch1500®, indicando que las harinas de mandioca poseen potencial para ser utilizadas 
como agentes desintegrantes en comprimidos.
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Artículo Original 
Original Article
Correspondencia 
Correspondence
Marta M.D.C. Vila
e-mail: marta.vila@prof.uniso.br
Financiación 
Fundings
No fundings received
Conflicto de interés 
Competing interest
The authors report no conflicts of 
interest whatsoever
Agradecimientos 
Acknowledgements
Fundação Dom Aguirre, for finantial 
support to Valéria Campos Orsi. Project 
funding by Fundação de Amparo à 
Pesquisa do Estado de São Paulo 
(FAPESP, São Paulo, Brazil) (FAPESP Ref. 
No. 2018/05522-9 (Project PsaPha-
geKill)) in the form of a BPE fellowship 
granted to Victor M. Balcão is hereby 
gratefully acknowledged. This work also 
received support from CNPq, National 
Council for Scientific and Technological 
Development Brazil, in the form of 
Research Productivity (PQ) fellowships 
granted to Victor M. Balcão (Refs. No. 
306113/2014-7 and 308208/2017-0).
Received: 13.05.2019 
Accepted: 19.08.2019
Bran of cassava starch flour and bran of cassava flour as potential 
tablet excipients
Salvado de harina y salvado de fécula de mandioca como potenciales excipientes 
para comprimidos
Valéria C. Orsi1, Marta M.D.C. Vila1*, Valquiría M. Hanai-Yoshida1, Marco V. Chaud2, Victor M. Balcão1,3, José M. 
Oliveira Jr.4
1 PhageLab – Laboratory of Biofilms and Bacteriophages, University of Sorocaba, 18023-000 Sorocaba/SP, Brazil.
2 LaBNUS – Laboratory of Biomaterials and Nanotechnology, University of Sorocaba, 18023-000 Sorocaba/SP, Brazil.
3 Department of Biology and CESAM, University of Aveiro, Campus Universitário de Santiago, P-3810-193 Aveiro, Portugal.
4 LaFINAU – Laboratory of Applied Nuclear Physics, University of Sorocaba, 18023-000 Sorocaba/SP, Brazil.
http://dx.doi.org/10.30827/ars.v60i4.9385
206 Ars Pharm. 2019; 60(4): 205-211
Orsi VC, et al.
INTRODUCTION
Growing expectations and demands regarding drug quali-
ty have been stimulating research and development of new 
pharmaceutical compounds. In the meantime, drug quality 
does not solely depend on the characteristics of the active 
principles and on the production process, but also on both 
the quality and functionality of the excipients utilized. (1-2) 
The excipients also influence in a significative fashion the 
release of the active principle contained in the medicine.
(3-4) During the production process, the intrinsic character-
istics of the (solid state) excipients as well as of the active 
principle are reflected in important parameters of the tab-
lets, such as compressibility, fluidity, ability to form uni-
form mixtures, lubrication, sedimentation and solubility.
(5-6) More and more, excipients are gaining increasing prom-
inence within pharmaceutical formulations, assuming 
now multiple functions critical to the effectiveness, safety 
and stability of the dosage forms.(7) Over recent years the 
pharmaceutical industry has been looking over alternative 
materials from plant origin possessing high starch content 
(5,8-10) that would, on one hand, allow to overcome certain 
difficulties inherent to the compression process in the pro-
duction of tablets and, on the other hand, exhibit economic 
feasibility. The brans of cassava (Manihot esculenta) flour 
and of cassava starch flour are residues arising from in-
dustrial processing of cassava to produce cassava flour and 
cassava starch flour and are therefore potential candidates 
for the development of new pharmaceutical materials and 
excipients to be used in pharmaceutical solid dosage forms 
aiment at oral administration. These brans possess a large 
amount of starch in their composition, low levels of impu-
rities, and can be produced in large scale and at a low cost 
(5,10,11). Hence, in this research effort the major goal was to 
characterize both the bran of cassava starch flour (Bsf) and 
the bran of cassava flour (Bf), and to fully assess their po-
tential as new tablet excipients.
MATERIALS AND METHODS
Materials
Samples of cassava brans were kindly supplied by Caio 
Prado Alimentos Ltda (Araras, Brazil), and were produced 
from cassava (Manihot esculenta Crantz) cultivar IAC 13. 
The brans were crushed in a Wiley-type mill (Marconi, 
model MA340, Piracicaba/SP, Brazil) and sieved (through a 
sieve with mesh opening of 0.850 mm, from Granutest, São 
Paulo, Brazil). As a model drug one used venlafaxine hy-
drochloride 99.32% pure (IdealFarma, Lot VHF 50071109, 
Anápolis, Goiás, Brazil). The excipient used for compari-
son purposes was Starch 1500® (Colorcon do Brasil, Lot IN 
517075, Cotia/SP, Brazil).
Experimental procedures
Physicochemical characterization of cassava brans
Organoleptic characteristics, appearance, odor and color of 
samples of brans of cassava starch flour (Bsf) and of cassava 
flour (Bf) were analyzed according to the Brazilian Phar-
macopoeia.(12) The contents in moisture, acidity, total ashes, 
lipid, protein, starch, fiber, and pH value, were determined 
according to the standards of the Institute Adolfo Lutz.(13) 
Bsf and Bf samples were also characterized according to 
their granulometry utilizing a sieving technique.(14) In or-
der to estimate the flow capacity one used the technique 
for determination of the angle at rest, the outflow time and 
apparent density.(14) The percentage compressibility index 
was determined via correlation between the apparent den-
sity and the compacted density (Lachman et al., 2001). For 
determination of the swelling index one used the specifica-
tions of the Brazilian Pharmacopoeia.(12)
Tablet production
The tablet formulations (Table1) were prepared using the 
technique of moist granulation.
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Table 1: Pharmaceutical formulae of the tablets prepared using bran of cassava starch flour (Bsf) bran of cassava flour (Bf) and 
Starch1500® as excipients
Ingredient
Formulation
I II III
Active 
con-
tent 
(mg)
mg/
tablet
Contri-
bution 
(%)
Active 
content 
(mg)
mg/
tablet
Contri-
bution 
(%)
Active 
content 
(mg)
mg/
tablet
Contribution 
(%)
Venlafaxine chlorhydrate 50 50 18.93 50 50 18.64 50 50 18.57
Bf 100 37.85 0 0 0 0
Bsf 0 0 100 37.29 0 0
Starch1500® 0 0 0 0 100 37.15
Tricalcium phosphate 77 29.14 77 28.71 77 28.60
Sodium bicarbonate 10 3.79 10 3.73 10 3.71
Carboxymethylcellulose 
(aq) 1 % (w/w) *
27 10.22 31 11.56 32 11.89
Magnesium stearate 0.2 0.08 0.2 0.07 0.2 0.07
Total 264 100.00 268 100.00 269 100.00
* sufficient amount to;
The defined granulometry for Bsf was of 0.300 mm, using 
sieve number 50, and for Bf one has used smaller granules 
(viz. 0.150 mm) using also sieve number 50. For this, all for-
mulation components were weighed and mixed (except for 
magnesium stearate and carboxymethylcellulose (CMC)) 
using the technique for geometric dilution of powders. 
CMC was dispersed in water (1%, w/v) and added to the 
mixture of powders, thus producing a malleable mass. The 
moist mass was then forced to pass through a sieve with 
mesh size of 3.35 mm. The moist mass was then forced 
to pass through a sieve with a mesh size of 3.35 mm. The 
moist granules thus produced were collected and scattered 
in an uniform fashion on a tray and subsequently dried in 
a circulation chamber set at 40 °C (Marconi, model MA035, 
Piracicaba/SP, Brazil). Following drying, the granules were 
placed in a porcelain mortar and crushed with the aid of a 
pestle, to reduce the granule size. The granules thus pro-
duced were then forced to pass through the mesh surface 
of a sieve number 40 and further mixed with 0.2% (w/w) 
of magnesium stearate. The granules retained in the mesh 
of sieve number 50 were subject to compression in an in-
strumented hydraulic press, (15) under two different average 
pressure forces, viz. 98 ± 5 MPa and 32 ± 6 MPa.
Hardness and friability trials of the tablet formulations
Hardness trials were performed in a manual durome-
ter (Nova Ética, model 298, Vargem Grande Paulista /SP, 
Brazil) and the friability tests were performed using a fria-
bilometer (Nova ética, model NT240, Vargem Grande Pau-
lista, /SP, Brazil) according the Brazilian Pharmacopoeia.(12)
Dissolution tests of the tablet formulations
The dissolutor (American Lab, model AL1000, Charqueada, 
/SP, Brazil) was used with a type-II apparatus (shaft) em-
ploying 900 mL of HCl 100 mM as dissolution medium, 
50 rpm of stirring speed and 37 ºC.(16) The concentration 
of venlafaxine hydrochloride was determined via UV-VIS 
spectrophotometry at 274 nm in a UV-VIS spectrophotome-
ter (Shimadzu, model 1501, Tokyo, Japan).
RESULTS AND DISCUSSION
Venlafaxine hydrochloride is selective serotonin reuptake 
inhibitor used in the treatment of depression; it was select-
ed as model drug for investigation because Venlafaxine hy-
drochloride is selective serotonin reuptake inhibitor used in 
the treatment of depression; it was selected as model drug 
for investigation because it was selected as model drug for 
investigation because it was selected as model drug for in-
vestigation because
The results of the physicochemical analyses performed to 
Bsf and Bf cassava bran samples are displayed in Table 2. 
The results obtained are compatible with the reference val-
ues (17-19) except for the lipid and ash contents.
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Table 2: Experimental results gathered from the physicochemical analyses performed to cassava starch flour (Bsf) and bran of cassava 
flour (Bf) samples
Parameter Reference value Bsf (%) Bf (%)
Moisture content* ≤ 16 % 12.92 ± 0.06 12.90 ± 0.09
pH* 4.5 a 7.0 5.54 ± 0.01 5.96 ± 0.01
Acidity* ≤ 2 % 1.973 ± 0.005 1.98 ± 0.01
Ashes* ≤ 0.6 % 0.87 ± 0.01 1.02 ± 0.02
Proteins* ≤ 0.3 % 0.35 ± 0.01 0.40 ± 0.12
Lipids** < 0.1 % 0.35 ± 0.02 0.45 ± 0.01
Fiber ----- 8.73 ± 0.68 5.50 ± 0.13
Starch ----- 74.46 ± 0.36 79.78 ± 0.43
Note: * USP 30 (2007); Portuguese Pharmacopoeia (2008); Rowe et al. (2009); ** Cereda, 1994.
The two cassava bran types possess enough concentrations 
in starch so that they can be utilized as tablet disintegrants. 
The observed indices of ash and lipid, above the standards 
established by USP 30(17) and Cereda (20) were probably due 
to several factors, namely the source of the raw material 
(vegetable origin), agronomic practices, milling proce-
dures, and chemical modifications that starch are prone 
to. The average size of particles obtained in cassava brans 
Bsf and Bf were determined after sieving because granule 
shape and granule size determine powder fluidity (Table 
3). In general, particles whose size varies between 0.25 mm 
and 2.0 mm do flow freely. With particles smaller in size 
than 0.1 mm, flow is a problem in most materials.(14)
Table 3: Results gathered from the granulometric analyses performed to cassava starch flour (Bsf) and, bran of cassava flour (Bf) sam-
ples
Average 
particle 
diameter 
(mm)
Bsf Bf
0.31 0.25
Sieve mesh Opening (mm) Bsf(100 g) % retained Bf (100 g) % retained
20 0.850 0.40 0.41 0.84 0.90
30 0.600 8.04 8.31 13.91 15.00
40 0.425 19.91 20.59 2.39 2.55
50 0.300 26.86 27.77 10.11 10.90
60 0.250 16.66 17.23 6.62 7.00
70 0.212 6.71 6.94 2.62 2.80
80 0.180 6.69 9.92 15.81 17.00
100 0.150 3.72 3.85 7.10 7.67
F < 100 0.125 7.72 7.98 33.34 36.18
Total 96.71 100 92.74 100
The results obtained for other physicochemical, charac-
teristics of the cassava bran (Bsf and Bf) granules are dis-
played in Table 4.
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Table 4: Physicochemical characteristics of cassava starch flour (Bsf) and bran of cassava flour (Bf) samples with respect to outflow time, 
angle at rest, apparent density, compacted density, and percent compactness index
Parameter
Bsf Bf
Sieve number /
(mesh opening, mm)
40/ (0.425) 50/ (0.30) 60/ (0.25) 80/ (0.18) 100/ (0.15)
Botton 
<0.15
OFT (min)
0.085 ± 
0.007
0.113 ± 
0.002
0.111 ± 
0.001
0.570 ± 
0.010
1.45 ± 0.56 1.48 ± 0.05
Â (°)
29.39 ± 
0.20
29.39 ± 
3.19
30.61 ± 
0.61
34.67 ± 
0.56
40.57 ± 
0.94
40.42 ± 
0.42
dapp (g mL
-1)
0.474 ± 
0.003
0.509 ± 
0.008
0.492 ± 
0.006
0.338 ± 
0.004
0.370 ± 
0.020
0.437 ± 
0.005
dcomp (g mL
-1)
0.554± 
0.003
0.574 ± 
0.009
0.559 ± 
0.007
0.470 ± 
0.005
0.540 ± 
0.001
0.697 ± 
0.004
CI (%)
16.273 ± 
0.005
13.630 ± 
0.010
13.637 ± 
0.005
38.890 ± 
0.001
51.510 ± 
0.010
61.400 ± 
5.210
Note: OFT – Outflow time; Â – Angle at rest; dapp – Apparent density; dcomp – Compacted density; CI – percent compactness index.
Powders with a low angle at rest, typically close to 25°, do 
flow freely, while those with high angles at rest, typically 
higher than 50°, display a bad flow.(4) A compressibility in-
dex (CI) with values smaller than 15% usually reflects an 
easy outflow of the sample particles, while values higher 
than 25% indicate a difficult flow of the particles.(21) Con-
sidering the aspects evaluated, the use of particles of Bsf 
resulting from sieves 40, 50, and 60 is not critical in the per-
formance of the tablet manufacturing process, and all have 
good flow characteristics, with CI between 13.63 and 16.27 
% (Table 4). However, the granules of Bf from sieve 80 may 
facilitate the manufacturing process due to a better flow of 
the particles, resulting in tablets with lower resistance to 
disintegration (CI of 38 %), although being bulkier (dcomp 
= 0.47 g mL-1). In spite of the fact that Bf particles resulting 
from sieve 80 displayed better flow characteristics and less 
resistance to disintegration, one opted to use the Bf parti-
cles from sieve 100, a powder defined as being semi-fine(12). 
Even though not presenting the best flow, the compacted 
density with a higher value (dcomp = 0.697 g mL
-1) indicates a 
more cohesive material, favoring the process of compaction 
(CI of 61.40%). For the Bsf particles, one opted to use in the 
pharmaceutical formulation the particles from sieve 50, a 
powder defined as being moderately coarse(12). In the gran-
ulometric distribution of Bsf the higher retention of parti-
cles occurred in mesh with size 0.3 mm (sieve 50), while 
for Bf the higher retention of particles was produced in the 
mesh with size lower than 150.0 µm. Therefore, the Bsf par-
ticle size in sieve 50 was higher than the Bf particle size in 
sieve with mesh the sizes smaller than 100. This is due to 
the greater amount of fiber present in Bsf bran, providing 
a more heterogeneous mixture where the starch is adhered 
to the fiber. Bsf has better flow characteristics due to both 
a low cohesion between the particles and their larger size, 
while Bf presents a worse fluidity due not only to the better 
cohesion between particles but also to their smaller size.
Experimental tests with cassava brans and with Starch1500® 
produced a higher swelling index of Bsf (360 ± 34%) when 
compared to that of Bf (180 ± 16 %). Starch1500® presented 
the highest swelling index (420 ± 5%). Inspite of the dif-
ferences in the swelling profile, the results obtained in this 
study indicate that cassava brans possess a high potential 
as disaggregating agents for pharmaceutical formulations.
(22,23)Venlafaxine hydrochloride was selected as model 
drug for this study due to its high aqueous solubility.(24) 
The other components employed in the formulations are 
commonly employed in the production of tablets.(4) The 
tablets of the three formulations produced with higher 
compression forces (160-200 MPa) resulted in tablets with 
a better appearance. The results obtained in the physical 
tests performed are displayed in Table 5. The values of dis-
integration time of a tablet are related to the processes of 
dissolution/absorption and, hence, to the bioavailability of 
the drug, while the hardness and friability of a tablet will 
define their physical stability.(24)
210 Ars Pharm. 2019; 60(4): 205-211
Orsi VC, et al.
Table 5: Results from physicochemical assays performed to tablet formulations I, II and III
Parameter
*Reference 
values
Tablet formulation
I II III
Pressure (MPa) ----- 98 ± 5 98 ± 5 98 ± 5
Weight (g) ----- 0. 263 ± 0.001 0. 270 ± 0.001 0.270 ± 0.001
Thickness (mm) ----- 1.76 ± 0.02 1.89 ± 0.07 1.763 ± 0.005
Friability % ≤ 1.5% 0.01 0.14 0.12
Hardness (N) ≥ 30N 90 ± 1 61.7 ± 0.6 70 ± 1
Note: * – acceptable limit, Brazilian Pharmacopoeia (2010).
The physical tests performed indicated a slightly differ-
ent behavior for Formulation I, higher hardness and null 
friability, compared to the other formulations. The tablets 
from formulation I made with Bf presented a better physi-
cal stability, providing them with a better appearance and 
resistance. The results of the desintegration tests were the 
same for both forces employed. In all samples, after a time 
period of 30 min, 100 % of the venlafaxine chlorhydrate was 
released. One can also infer that, being the disintegration of 
a tablet an action usually prior to the dissolution process, Bf 
and Bsf produced a fast disintegration time thus confirm-
ing the potential of cassava brans as tablet disintegrants.
CONCLUSIONS
Formulation I presented better physical stability, physic-
ochemical and pharmacotechnical characteristics as com-
pared to formulations II and III. The tests performed on the 
tablets produced using Bsf and Bf cassava brans revealed 
that these brans exhibit physicochemical characteristics 
very similar to those presented by Starch1500®. It can be 
concluded that the cassava by-products Bf and Bsf could 
replace with advantage the excipients traditionally used by 
the pharmaceutical industry to produce tablets.
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